Logo image of ZLNA.OL

ZELLUNA ASA (ZLNA.OL) Stock Fundamental Analysis

OSL:ZLNA - Euronext Oslo - NO0013524942 - Common Stock - Currency: NOK

13.18  -0.42 (-3.09%)

Fundamental Rating

2

Taking everything into account, ZLNA scores 2 out of 10 in our fundamental rating. ZLNA was compared to 73 industry peers in the Biotechnology industry. While ZLNA seems to be doing ok healthwise, there are quite some concerns on its profitability. ZLNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ZLNA had negative earnings in the past year.
ZLNA had a negative operating cash flow in the past year.
In the past 5 years ZLNA always reported negative net income.
In the past 5 years ZLNA always reported negative operating cash flow.
ZLNA.OL Yearly Net Income VS EBIT VS OCF VS FCFZLNA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of ZLNA (-173.53%) is worse than 80.82% of its industry peers.
ZLNA has a worse Return On Equity (-243.21%) than 63.01% of its industry peers.
Industry RankSector Rank
ROA -173.53%
ROE -243.21%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZLNA.OL Yearly ROA, ROE, ROICZLNA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZLNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZLNA.OL Yearly Profit, Operating, Gross MarginsZLNA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

More info and screens

4

2. Health

2.1 Basic Checks

ZLNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZLNA.OL Yearly Shares OutstandingZLNA.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ZLNA.OL Yearly Total Debt VS Total AssetsZLNA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -11.47, we must say that ZLNA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.47, ZLNA is not doing good in the industry: 78.08% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that ZLNA is not too dependend on debt financing.
ZLNA has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. ZLNA outperforms 94.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.47
ROIC/WACCN/A
WACCN/A
ZLNA.OL Yearly LT Debt VS Equity VS FCFZLNA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

ZLNA has a Current Ratio of 3.62. This indicates that ZLNA is financially healthy and has no problem in meeting its short term obligations.
ZLNA has a better Current ratio (3.62) than 69.86% of its industry peers.
ZLNA has a Quick Ratio of 3.62. This indicates that ZLNA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.62, ZLNA is doing good in the industry, outperforming 73.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.62
ZLNA.OL Yearly Current Assets VS Current LiabilitesZLNA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

ZLNA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.77%.
EPS 1Y (TTM)-5.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ZLNA will show a very strong growth in Earnings Per Share. The EPS will grow by 35.22% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.94%
EPS Next 2Y35.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZLNA.OL Yearly Revenue VS EstimatesZLNA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2M 4M 6M 8M
ZLNA.OL Yearly EPS VS EstimatesZLNA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZLNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZLNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZLNA.OL Price Earnings VS Forward Price EarningsZLNA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZLNA.OL Per share dataZLNA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as ZLNA's earnings are expected to grow with 35.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.22%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZLNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZELLUNA ASA

OSL:ZLNA (5/27/2025, 7:00:00 PM)

13.18

-0.42 (-3.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08
Earnings (Next)08-20 2025-08-20
Inst Owners18.55%
Inst Owner ChangeN/A
Ins Owners6.3%
Ins Owner ChangeN/A
Market Cap266.63M
Analysts42.22
Price Target58.65 (344.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.23
P/tB 3.23
EV/EBITDA N/A
EPS(TTM)-5.81
EYN/A
EPS(NY)-5.25
Fwd EYN/A
FCF(TTM)-8.08
FCFYN/A
OCF(TTM)-8.08
OCFYN/A
SpS0
BVpS4.09
TBVpS4.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -173.53%
ROE -243.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.61%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 3.62
Altman-Z -11.47
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2.96%
Cap/Depr(5y)41.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90.69%
EPS Next Y87.94%
EPS Next 2Y35.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.92%
OCF growth 3YN/A
OCF growth 5YN/A